Invesco Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNA

Invesco Ltd. acquired a new position in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,296 shares of the company's stock, valued at approximately $209,000.

A number of other large investors also recently added to or reduced their stakes in VRNA. NBC Securities Inc. acquired a new position in Verona Pharma PLC American Depositary Share during the first quarter worth $34,000. Vermillion Wealth Management Inc. acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the fourth quarter valued at about $46,000. GF Fund Management CO. LTD. acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the fourth quarter valued at about $72,000. Advisors Preferred LLC raised its position in shares of Verona Pharma PLC American Depositary Share by 65.4% in the first quarter. Advisors Preferred LLC now owns 1,599 shares of the company's stock valued at $94,000 after buying an additional 632 shares during the last quarter. Finally, Avanza Fonder AB acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the first quarter valued at about $100,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Verona Pharma PLC American Depositary Share Trading Down 0.0%

Shares of VRNA stock opened at $106.30 on Tuesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54. The firm has a market cap of $9.19 billion, a PE ratio of -107.37 and a beta of 0.14. The company has a 50-day moving average of $103.55 and a two-hundred day moving average of $82.51. Verona Pharma PLC American Depositary Share has a 1-year low of $25.79 and a 1-year high of $106.44.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.14. The company had revenue of $103.14 million during the quarter, compared to analyst estimates of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. On average, analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Mark W. Hahn sold 400,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total value of $4,560,000.00. Following the completion of the transaction, the chief financial officer owned 12,278,992 shares of the company's stock, valued at approximately $139,980,508.80. This trade represents a 3.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Andrew Fisher sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $11.53, for a total transaction of $922,400.00. Following the completion of the transaction, the general counsel directly owned 359,999 shares of the company's stock, valued at approximately $4,150,788.47. The trade was a 18.18% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,420,584 shares of company stock valued at $17,145,674. 4.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

VRNA has been the subject of a number of recent research reports. Truist Financial cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Zacks Research upgraded shares of Verona Pharma PLC American Depositary Share to a "hold" rating in a research report on Friday, August 8th. HC Wainwright restated a "neutral" rating and set a $107.00 price objective (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, July 14th. BTIG Research cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Finally, Piper Sandler cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Two analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Want to see what other hedge funds are holding VRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.